KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Inovio Pharmaceuticals (INO) Return on Capital Employed (2016 - 2025)

Inovio Pharmaceuticals (INO) has disclosed Return on Capital Employed for 15 consecutive years, with 3.08% as the latest value for Q4 2025.

  • Quarterly Return on Capital Employed fell 158.0% to 3.08% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 3.08% through Dec 2025, down 158.0% year-over-year, with the annual reading at 1.73% for FY2025, 68.0% down from the prior year.
  • Return on Capital Employed hit 3.08% in Q4 2025 for Inovio Pharmaceuticals, down from 88.76% in the prior quarter.
  • In the past five years, Return on Capital Employed ranged from a high of 88.76% in Q3 2025 to a low of 3.08% in Q4 2025.
  • Historically, Return on Capital Employed has averaged 3.39% across 5 years, with a median of 1.0% in 2022.
  • Biggest YoY gain for Return on Capital Employed was 8999bps in 2025; the steepest drop was -158bps in 2025.
  • Year by year, Return on Capital Employed stood at 0.67% in 2021, then plummeted by -46bps to 0.98% in 2022, then dropped by -5bps to 1.03% in 2023, then tumbled by -46bps to 1.5% in 2024, then crashed by -105bps to 3.08% in 2025.
  • Business Quant data shows Return on Capital Employed for INO at 3.08% in Q4 2025, 88.76% in Q3 2025, and 2.08% in Q2 2025.